ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing
ImmunityBio shares jumped 27% to $7 in premarket trading after the company said the FDA requested more data, but no new trials, for a possible resubmission of its ANKTIVA bladder cancer treatment. The company plans to submit the additional information within 30 days. Investors are watching for the FDA’s response and any signal of a formal review.
